Scilex Holding Company announced that it has received $101.875 million in funding from Oramed Pharmaceuticals Inc.
The company has received 101,875,000 pursuant to Regulation D and included participation from single investor.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8805 USD | +2.29% | -1.93% | -56.84% |
Apr. 16 | Scilex Issues Preliminary Q1 Sales Results for ZTlido | MT |
Mar. 20 | Scilex Seeks FDA Approval to Add Dosing Guidance to Gout Treatment Drug Label | MT |
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
2.46 USD | +6.96% | +8.37% | 99.68M | ||
0.8805 USD | +2.29% | -1.93% | 107M | ||
1st Jan change | Capi. | |
---|---|---|
-56.84% | 107M | |
+5.31% | 70.44B | |
+10.97% | 8.94B | |
-16.83% | 4.75B | |
+43.48% | 4.5B | |
+3.20% | 3.85B | |
+18.82% | 2.38B | |
-21.36% | 2.34B | |
-29.67% | 2.2B | |
+8.38% | 1.96B |